Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
September 13, 2024
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
Federal health officials indicated a shift in the ongoing fight against HIV and AIDS when the CDC announced Wednesday new clinical guidelines that encourage the use of pre-exposure prophylaxis, or PrEP.
Educating people about the availability of PrEP shouldn't be controversial, writes Dr. Michael Gottlieb.
Condoms are "morally complicated for the church," the pontiff says.
Scientists have
long believed that a vaccine is the best way to stop the
spread of HIV, but efforts to invent one have failed
miserably. Now they may have found something already
on pharmacy shelves that seems to prevent infection.